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Riboflavin can be described as a biological chelating ligand due to the existence of nitrogen and oxygen atoms on its structure 
that can act as coordinating sites for metal ion on chelation. Co (II) with Riboflavin have been synthesized and characterized by IR, 
LC-MS, UV, TG-DTA confirms the coordination of ligand. Complex is screened for Anti-microbial activity and Cytotoxicity. 
Keywords: Cytotoxicity, Differential thermal analysis (DTA), Riboflavin 
Many of the biologically active agents are complexes 
and even the simpler types of chelating compounds 
have served as model compounds in bodily process 
and the living system is partially supported by 
coordination complexes. In literature, the use of 
transition metal complexes as therapeutic compounds 
has become more and more pronounced
1-35
. Metals 
like Copper, Nickel, Cobalt and Zinc are bio essential 
elements and responsible for numerous bio-activities 
in living organism. Riboflavin (7, 8-dimethyl-10-
ribityl-isoalloxazine) is a water soluble vitamin 
present in a wide variety of foods. Its metabolism is 
controlled by different hormones which regulate its 
conversion in flavin adenine dinucleotide and flavin 
mononucleotide
36
. These two coenzymes catalyse 
many oxidation-reduction reactions and are essential 
for production of energy
37,38
. The risk of cancer at 
certain site increase due to Riboflavin deficiency, in 
some cases Riboflavin reduces the effect of 
carcinogen this is due to metabolism by flavin- 
dependent enzymes. Literature survey shows that the 
synthesis and characterization of Riboflavin 
complexes have not been fully exploited by 
researchers. In this paper we present the synthesis and 
bio-chemistry of Riboflavin complexes with cobalt.  
 
Materials and Methods 
Chemicals  
All chemical reagents and solvents used were of 
analytical grade and used without further purification 
and used as received.  
Instruments 
IR spectra are obtained with a Shimadzu IR 
Prestige 21 FT-IR spectrophotometer. Electronic 
spectra are recorded on Labindia UV3000
+
 UV- VIS 
spectrophotometer. LC-MS Spectra is recorded  
on Agilent QQQ (ESI-MS) mass spectrometer.  
TG-DTA spectra are obtained using SDT Q600 V20.9 
BUILD 20.  
 
Synthesis of metal complex 
A methanolic (10 mL) solution of Cobalt nitrate 
(0.219 g, 1.0 mM) is added to a sodium hydroxide 
solution (10 mL) of Riboflavin (0.376 g, 1.0 mM) 
resulted into brown precipitate under stirring 
conditions. After constant stirring at room 
temperature for 30 min, the solution turned to 
yellowish brown and is filtered off, later green 
precipitate is formed. It is washed with methanol. 
Yield is 0.428 g (72%). 
 
Results and Discussion 
Characterization of metal complexes 
IR spectrum of complex 
The strong vibration bands at 1733 cm
−1
 and  
1666 cm
−1
 in Riboflavin were assigned as ν (C=O) 
stretching vibration. In Riboflavin, the band shifted  
to the range 1647 cm
−1
 in the Cobalt (II) complexes, 
respectively. This confirmed the coordination  
of Riboflavin via carbonyl oxygen atom.  
The azomethine, ν (C=N) stretching vibration at  
1649-1546 cm
−1
 in Riboflavin shifted in the Cobalt 
(II) complexes to 1647-1544 cm
−1
 indicative of 
coordination of the imine nitrogen to the Cobalt (II) 
—————— 
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ions. The broad band at 3384 cm
−1 
is indicative of 
coordination of the ν (OH) of coordinated water 
molecules.  
 
LC-MS spectrum 
The peak at 139 (m/z) correspond to C5H11O4 (part) 
of Riboflavin ligand and at 245 (m/z) is C12H9N4O2. 
The peak at 484 (m/z) correspond to cobalt bound  
to three water molecules refer to [Co(Ribo)3H2O].  
The peaks around 505 (m/z) refer to cobalt  
bound to Riboflavin and four water molecules 
[Co(Ribo)4H2O].  
 
Electronic spectrum of complex 
The UV–VIS spectrum of the cobalt complexes  
are recorded in DMF solution in the wavelength  
range 200–800 nm. The electronic spectrum of  
Co (II) complex showed bands at 280 nm and  
380 nm assignable to d-d transitions,  
respectively, which are characteristic to the octahedral 
configuration. 
 
Thermogravimetric analysis 
TG-DTA spectrum of complex: Thermal 
decomposition of the complex takes place in  
three stages. In the first stage evaporation of  
water takes in between 100-200C with a mass loss  
of 14% (obs 16.7%). The maximum rate of mass  
loss is indicated by DTA peak at 150C. After  
the evaporation of water thermal degradation of 
ligand starts which is the second stage takes on  
place at 200-300C with mass loss of 52.5%  
(obs 59.5%) which is indicated by DTA peak  
at 250C. The third stage is complete decomposition 
of Riboflavin takes place between 300-500C  
with mass loss of 86.4% (obs 89.3%). The  
maximum rate of mass loss is indicated by DTA  
peak at 450C. The end product estimated is oxide of 
cobalt (Fig. 1). 
 
Proposed structure of [Co(Ribo)4(H2o)]  
In the title mono nuclear complex [Co 
(Ribo)4H2O] Co (II) is coordinated by one  
oxygen and one nitrogen from Riboflavin and  
oxygen of four aqua ligands. Co (II) in the complex 
adopts perfect distorted octahedral based structure 
(Fig. 2). 
 
Antimicrobial screening of [Co(Ribo)4(H2o)]  
The complex is screened in vitro for Antibacterial 
activity against E. coli, S. aureus, by Disc diffusion 
method. The Antimicrobial activities of complex are 
listed in (Table 1). 
 
 
Fig. 1 — Cobalt Riboflavin Complex (A) IR Spectrum; (B) LC-MS Spectrum; (C) UV-Visible Spectrum; (D) TG Spectrum; and  
(E) DTA Gram  
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The in vitro antimicrobial properties cobalt mixed 
ligand complex are tested against these gram–positive 
and gram–negative bacteria- S. aureus, P. aeruginosa, 
E. coli the diameters of the inhibition zone equal 3.5 
and 2 mM, respectively, and no inhibition zone found 
for E. coli (Fig. 3).  
 
Cytotoxic studies  
The complex is screened for its Cytotoxicity  
MCF-7, A-431 and HepG-2 Cell lines. From the data, 
it is observed that the complex displayed their 
Cytotoxicity activities as IC50 (μg/mL) against  
MCF-7, A-431 and HepG-2 Cell lines. The IC50 
values of the all the complexes are listed in (Table 2). 
Complex displayed low Cytotoxicity activities. 
Cytotoxicity results indicated that all tested complexes 
(IC50 = 440–500 μg/mL) (Fig. 4 & Table 3). 
Table 2 — Dose response of complex on MCF-7 cell line 
incubation time 24 h 
Conc (µg/mL) OD of 
extract 
% Cell 
Survival 
% Cell inhibition 
 0.584 100 0 
0.1 0.5605 95.97 4.03 
1 0.538 92.12 7.88 
10 0.513 87.84 12.16 
100 0.443 75.85 24.15 
500 0.3075 52.65 47.35 
Dose response of complex on A-431 cell line incubation time  
24 h 
 0.8655 100 0 
0.1 0.742 85.73 14.27 
1 0.74 85.49 14.51 
10 0.688 79.49 20.51 
100 0.6785 78.39 21.61 
500 0.44 50.83 49.17 
Dose response of complex on HEPG-2 cell line incubation time 
24 h 
 0.838 100 0 
0.1 0.7775 92.78 7.22 
1 0.6945 82.87 17.13 
10 0.604 72.07 27.93 
100 0.5285 63.06 36.94 
500 0.4 47.73 52.27 
 
 
 
 
Fig. 4 — Effect of complex on (A) MCF-7; (B) A-431; and  
(C) HepG-2 cell viability for 24 h incubation time 
 
 
Fig. 2 — Synthetic route and proposed structure of complex 1 
 
Table 1 — Inhibition zones for complex in comparison with 
standard drug 
Bacteria Inhibition zone 
(mM) 
Streptomycin 
E. Coli Nil 1.8 
S. aureus 3.5 1.7 
P. aeruginosa 2 1.9 
 
 
 
Fig. 3 — Inhibition zones for complex against (A) S. aureus,  
E. coli; and (B) P. aeruginosa  
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Conclusion 
This complex which had been studied for 
Antimicrobial activity proved to have better activity 
than the standard drug like streptomycin. This 
complex is also studied for cytotoxicity and is found 
to exhibit activity. From the current research 
Riboflavin deficiency has been suggested as a risk 
factor for cancer, hence coordination of Riboflavin 
with cobalt are good candidates exhibiting both 
microbial activity and cytotoxicity on further 
preclinical studies may lead to development as 
effective therapeutic strategies for treating cancer. 
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